Paliperidone NEW
| Price | $50 | $88 | $252 |
| Package | 50mg | 100mg | 500mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Paliperidone | CAS No.: 144598-75-4 |
| Purity: 95.00% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Paliperidone |
| Description | Paliperidone (9-hydroxyrisperidone)(Invega) is used as an atypical antipsychotic. It applies to the acute and maintenance treatment of schizophrenia. Chemically, paliperidone is the primary active metabolite of the older atypical antipsychotic risperidone. |
| In vitro | Paliperidone significantly increases the intracellular accumulation of Rh123 and DOX in a concentration-dependent manner. [1] Paliperidone works finely at low concentrations (10 and 50 μM) against Aβ(25-35) and MPP(+) and solely protects SH-SY5Y from hydrogen peroxide. Paliperidone (100 μM) completely diminishes cell reduction induced by different stressors, regardless of their dosages. Paliperidone is demonstrated with higher oxidative stress-scavenging properties than other APDs in several aspects, such as generated bulk glutathione, low HNE, and protein carbonyl productions. [2] Paliperidone enhances dopamine toxicity at the highest dose and is the only AP that significantly increases cell viability (8.1%) compared with cells treated with dopamine alone. [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4.3 mg/mL (10.08 mM), Sonication is recommended. |
| Keywords | β-adrenergic receptor | Serotonin Receptor | schizophrenia | Paliperidone | metabolite | Inhibitor | inhibit | HistamineReceptor | Histamine Receptor | H1 receptor | DopamineReceptor | Dopamine Receptor | Dopamine | Beta Receptor | atypical | antipsychotic | AdrenergicReceptor | Adrenergic Receptor | 5-hydroxytryptamine Receptor | 5HTReceptor | 5-HT Receptor | 5HT Receptor | 5-HT |
| Inhibitors Related | Undecane | 2-(Methylamino)benzoic acid | Alverine citrate | Meclizine dihydrochloride | Dapoxetine hydrochloride | Hexamethonium Bromide | Famotidine | 1,8-Cineole | 10-Undecen-1-ol | Sodium butanoate | Alginic acid | Cinchonidine |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
-
![3-Phenyl-n-[1-(phenylmethyl)-4-piperidinyl]-tricyclo[3.3.1.13,7]decane-1-carboxamide](https://img.chemicalbook.com/ProductImageEN2/2025-11/Large/f8219d67-7068-46e7-971a-659e7ef212f7.png)
CAS:1252187-41-9
$56.00
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-04 | ||
|
VIP5Y
|
Sinoway Industrial co., ltd.
|
2026-06-03 | ||
|
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-05-20 | ||
| $88.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $65.00 |
VIP3Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2026-05-05 | |
|
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2026-02-02 | ||
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-12-01 | ||
|
VIP4Y
|
Dingwang Technology (Wuhan) Co., Ltd.
|
2025-08-22 | ||
| $88.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-04-28 | |
|
VIP3Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2025-04-02 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY